Trastuzumab emtansine (T-DM1), the first HER2-targeted ADC approved for metastatic HER2-positive BC, consists of an anti-HER2 antibody linked via a non-cleavable thioether to the tubulin polymerization inhibitor, DM1, which induces cell death [18]. The gene discussed is ERBB2; the disease is breast cancer.